GoodRx Holdings (GDRX) Total Non-Current Liabilities (2019 - 2026)

GoodRx Holdings has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $1.4 billion for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $1.4 billion, up 119.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 119.33% YoY), and the FY2025 annual result was $779.1 million, up 18.64% from the prior year.
• Total Non-Current Liabilities came in at $1.4 billion for Q1 2026 at GoodRx Holdings, up from $779.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.4 billion in Q1 2026 to a low of $634.0 million in Q1 2025.
• The 5-year median for Total Non-Current Liabilities is $776.0 million (2023), against an average of $786.8 million.
• Across the five-year window, Total Non-Current Liabilities fell 22.16% in 2025 and surged 119.33% in 2026, its largest moves.
• GoodRx Holdings' Total Non-Current Liabilities stood at $782.2 million in 2022, then grew by 4.66% to $818.7 million in 2023, then retreated by 19.79% to $656.7 million in 2024, then gained by 18.64% to $779.1 million in 2025, then soared by 78.49% to $1.4 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.4 billion (Q1 2026), $779.1 million (Q4 2025), and $717.2 million (Q3 2025), per Business Quant data.